Top

21-03-2017 | Osteoporosis | Case report | Article

Case report: fast reversal of severe osteoporosis after correction of excessive levothyroxine treatment and long-term follow-up

Journal: Osteoporosis International

Authors: C. M. Laine, K. Landin-Wilhelmsen

Publisher: Springer London

Abstract

Summary

This case report describes a 38-year-old woman, who presented with bilateral femoral stress fractures and osteoporosis after years of excessive levothyroxine treatment. Her bone health was restored rapidly and long-lasting with the reduction of levothyroxine dosage. No bone-active treatment was warranted.

Introduction

Hyperthyroidism is a known risk factor for osteoporosis and fractures. Recent studies on patients with serum thyrotropin-suppressive therapy have not, however, indicated adverse effects on bone during long-term follow-up.

Methods

This case report describes long-term follow-up data of a clinically euthyreoid patient, who developed symptomatic osteoporosis due to excessive levothyroxine treatment.

Results

After correction of levothyroxine dosage, her bone mineral density (BMD) and previously elevated serum osteocalcin levels normalized rapidly and she remained free from fractures during 23 years of follow-up over menopause.

Conclusion

Excessive TSH suppression contributed to the secondary osteoporosis in this patient; BMD normalized after dose reduction of levothyroxine and no fractures occurred during 23 years’ follow-up. Some patients develop severe osteoporosis if they are over-substituted with levothyroxine, and decent follow-up of patients with levothyroxine supplementation is mandatory.

Taylor PN, Razvi S, Pearce SH, Dayan CM (2013) Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab 98(9):3562–3571CrossRefPubMed

Leader A, Ayzenfeld RH, Lishner M, Cohen E, Segev D, Hermoni D (2014) Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years. J Clin Endocrinol Metab 99(8):2665–2673CrossRefPubMed

Noh HM, Park YS, Lee J, Lee W (2015) A cross-sectional study to examine the correlation between serum TSH levels and the osteoporosis of the lumbar spine in healthy women with normal thyroid function. Osteoporos Int 26(3):997–1003CrossRefPubMed

Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP (2010) Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 95(1):186–193CrossRefPubMed

Lee MY, Park JH, Bae KS, Jee YG, Ko AN, Han YJ, Shin JY, Lim JS, Chung CH, Kang SJ (2014) Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Ann Surg Treat Res 86(2):55–60CrossRefPubMedPubMedCentral

Leonova TA, Drozd VM, Saenko VA, Mine M, Biko J, Rogounovitch TI, Takamura N, Reiners C, Yamashita S (2015) Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not calcium-D3 supplementation. Endocr J 62(2):173–182CrossRefPubMed

Hind K, Zanker C, Truscott J (2011) Five-year follow-up investigation of bone mineral density by age in premenopausal elite-level long-distance runners. Clin J Sport Med 21(6):521–529CrossRefPubMed

Kobe N, Takamatsu J, Ito M, Sakane S, Ohsawa N (1999) Acute and early effects of triiodothyronine administration on serum markers of bone and mineral metabolism. Endocrine 10(1):53–56CrossRefPubMed

Yoshihara A, Yoshimura Noh J, Mukasa K, Watanabe N, Iwaku K, Ohye H, Suzuki M, Matsumoto M, Kunii Y, Suzuki N, Endo K, Suzuki R, Hattori N, Sugino K, Ito K (2016) The characteristics of osteoporotic patients in Graves’ disease patients newly diagnosed after menopause: a prospective observational study. Endocr J

10.

Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 332(12):767–773CrossRefPubMed

11.

Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk—a meta-analysis. Thyroid 13(6):585–593CrossRefPubMed

12.

Abrahamsen B, Jorgensen HL, Laulund AS, Nybo M, Brix TH, Hegedus L (2014) Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures—the OPENTHYRO register cohort. J Bone Miner Res 29(9):2040–2050CrossRefPubMed

13.

Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodeling. Cell 115(2):151–162CrossRefPubMed

14.

Nicholls JJ, Brassill MJ, Williams GR, Bassett JH (2012) The skeletal consequences of thyrotoxicosis. J Endocrinol 213(3):209–221CrossRefPubMed

15.

Baliram R, Sun L, Cao J, Li J, Latif R, Huber AK, Yuen T, Blair HC, Zaidi M, Davies TF (2012) Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest 122(10):3737–3741CrossRefPubMedPubMedCentral

16.

Tournis S, Antoniou JD, Liakou CG, Christodoulou J, Papakitsou E, Galanos A, Makris K, Marketos H, Nikopoulou S, Tzavara I, Triantafyllopoulos IK, Dontas I, Papaioannou N, Lyritis GP, Alevizaki M (2015) Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol 82(2):197–204CrossRef

17.

Jodar E, Munoz-Torres M, Escobar-Jimenez F, Quesada-Charneco M, Lund del Castillo JD (1997) Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol 47(3):279–285CrossRef

18.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133CrossRefPubMedPubMedCentral